Skip to main content

S1.

S1

A flowchart of patient cohort. NSCLC, non-small cell lung cancer; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; *, patients who: 1) only accepted epidermal growth factor receptor (EGFR) mutation status tests but refused following standard therapies, or 2) transferred to local hospitals for continuous therapies but standardized treatments cannot be guaranteed; **, post-treatment T790M mutations which are not included in our analyses.